en.Wedoany.com Reported - Evotec SE announced the appointment of Rui Wang as Global Head of Computational Science and Artificial Intelligence, aiming to drive the integration of computational science and data-driven decision-making processes across the entire R&D landscape, developing enterprise-level solutions to make AI and computational science methods a cornerstone of Evotec's commercial value creation.

Evotec CEO Christian Wojczewski stated that Rui will play a central role in driving drug discovery and development to become a powerful engine of innovation, integration, and operational efficiency. He added that advanced computational technologies are critical to enhancing value across the company's business areas—drug discovery and preclinical development, as well as Just - Evotec Biologics—and that these technologies are not isolated elements but integral components of all activities aimed at discovering and developing new therapies.

Prior to joining Evotec, Rui Wang served as Head of Data, Analytics, and Artificial Intelligence at AstraZeneca, where he worked for over a decade. He previously worked at the European Bioinformatics Institute of the European Molecular Biology Laboratory and at Tangram Therapeutics (formerly e-therapeutics). He holds a Master's degree in Bioinformatics from the University of Manchester and a Master's degree in Internet Application Systems Design from Newcastle University.

Rui Wang, Global Head of Computational Science and Artificial Intelligence at Evotec, stated that in AI-driven drug discovery, companies that learn from the right data—data generated at scale around key biological questions—will take the lead. He believes Evotec is uniquely positioned at the intersection of research, data, and proprietary platforms, with the goal of transforming this advantage into a sustainable scientific competitive edge by further developing and scaling differentiated capabilities with the necessary depth and rigor.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com